We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report?
Read MoreHide Full Article
It has been about a month since the last earnings report for Fate Therapeutics (FATE - Free Report) . Shares have added about 18.7% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Fate Therapeutics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
FATE Q2 Earnings Beat on Lower Expenses, Collaboration Revenues Grow
Fate reported a loss of 33 cents per share in the second quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 47 cents. The company reported a loss of 54 cents per share in the year-ago period.
The loss narrowed year over year due to higher collaboration revenues and lower R&D expenses.
The company earned collaboration revenues of $6.8 million, which beat the Zacks Consensus Estimate of $1 million. The figure also increased from $0.9 million reported in the year-ago quarter.
The strong top-line results can be attributed to the achievement of a $5 million milestone payment in connection with the clinical development of FT825/ONO-8250 and the conduct of preclinical development activities for a second collaboration candidate targeting an undisclosed solid tumor antigen under its collaboration with Ono.
R&D expenses declined 15.4% to $34.6 million. G&A expenses decreased 23.7% to $17.2 million.
Cash, cash equivalents and investments as of Jun 30, 2024, totaled $352.0 million.
Fate is focused on the development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. Its immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cells and T-cell product candidates.
A phase I study of FT819, a T-cell product candidate for patients with systemic lupus erythematosus (SLE), is currently enrolling patients. The first patient enrolled in the study was a 27-year-old woman diagnosed with lupus nephritis (over ten years ago). She received conditioning chemotherapy followed by a single dose of FT819 at 360 million cells.
The patient remains on study. There has not been any grade ≥3 adverse event or incidence of any grade of cytokine release syndrome (CRS), immune effector-cell associated neurotoxicity syndrome (ICANS), or graft-versus-host disease (GvHD). FATE plans to present clinical and translational data from the Phase 1 study at a medical conference in the second half of 2024.
Fate also amended the clinical protocol of its phase I autoimmunity study on FT819 to include single-agent cyclophosphamide as a third conditioning regimen.
The company successfully completed dose escalation in its phase I B cell malignancies study on FT819 and has focused further on clinical development of FT819, exclusively in autoimmunity.
With ONO Pharmaceutical, Fate is co-developing FT825/ONO-8250, a multiplexed-engineered, iPSC-derived CAR T-cell product candidate. Fate is conducting a multi-center, phase I study to assess the safety, pharmacokinetics and activity of FT825/ONO-8250 as monotherapy and in combination with monoclonal antibody therapy in patients with advanced solid tumors.
Three patients have been treated in the phase I study with a single dose of FT825 / ONO-8250 as monotherapy at the first dose level of 100 million cells. Fate plans to present clinical and translational data from the phase I study at a medical conference in the second half of 2024.
A phase I study of FT522 in patients with relapsed/refractory B-cell lymphoma is also ongoing. The first patient has now been treated in the first three-dose cohort at 300 million cells per dose without conditioning chemotherapy. In addition, the first patient has now been treated in the second three-dose cohort at 900 million cells per dose with conditioning chemotherapy (Regimen A). No dose-limiting toxicity or event of any grade of CRS, ICANS, or GvHD has been reported.
Fate plans to submit an investigational new drug application to the FDA in the third quarter of 2024 for the treatment of a basket of B cell-mediated autoimmune diseases with FT522, without any administration of conditioning chemotherapy to patients.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in estimates revision.
The consensus estimate has shifted 12.33% due to these changes.
VGM Scores
At this time, Fate Therapeutics has an average Growth Score of C, however its Momentum Score is doing a bit better with a B. However, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Fate Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Fate Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, SpringWorks Therapeutics (SWTX - Free Report) , a stock from the same industry, has gained 8.9%. The company reported its results for the quarter ended June 2024 more than a month ago.
SpringWorks Therapeutics reported revenues of $59.73 million in the last reported quarter, representing a year-over-year change of
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report?
It has been about a month since the last earnings report for Fate Therapeutics (FATE - Free Report) . Shares have added about 18.7% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Fate Therapeutics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
FATE Q2 Earnings Beat on Lower Expenses, Collaboration Revenues Grow
Fate reported a loss of 33 cents per share in the second quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 47 cents. The company reported a loss of 54 cents per share in the year-ago period.
The loss narrowed year over year due to higher collaboration revenues and lower R&D expenses.
The company earned collaboration revenues of $6.8 million, which beat the Zacks Consensus Estimate of $1 million. The figure also increased from $0.9 million reported in the year-ago quarter.
The strong top-line results can be attributed to the achievement of a $5 million milestone payment in connection with the clinical development of FT825/ONO-8250 and the conduct of preclinical development activities for a second collaboration candidate targeting an undisclosed solid tumor antigen under its collaboration with Ono.
R&D expenses declined 15.4% to $34.6 million. G&A expenses decreased 23.7% to $17.2 million.
Cash, cash equivalents and investments as of Jun 30, 2024, totaled $352.0 million.
Fate is focused on the development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. Its immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cells and T-cell product candidates.
A phase I study of FT819, a T-cell product candidate for patients with systemic lupus erythematosus (SLE), is currently enrolling patients. The first patient enrolled in the study was a 27-year-old woman diagnosed with lupus nephritis (over ten years ago). She received conditioning chemotherapy followed by a single dose of FT819 at 360 million cells.
The patient remains on study. There has not been any grade ≥3 adverse event or incidence of any grade of cytokine release syndrome (CRS), immune effector-cell associated neurotoxicity syndrome (ICANS), or graft-versus-host disease (GvHD). FATE plans to present clinical and translational data from the Phase 1 study at a medical conference in the second half of 2024.
Fate also amended the clinical protocol of its phase I autoimmunity study on FT819 to include single-agent cyclophosphamide as a third conditioning regimen.
The company successfully completed dose escalation in its phase I B cell malignancies study on FT819 and has focused further on clinical development of FT819, exclusively in autoimmunity.
With ONO Pharmaceutical, Fate is co-developing FT825/ONO-8250, a multiplexed-engineered, iPSC-derived CAR T-cell product candidate. Fate is conducting a multi-center, phase I study to assess the safety, pharmacokinetics and activity of FT825/ONO-8250 as monotherapy and in combination with monoclonal antibody therapy in patients with advanced solid tumors.
Three patients have been treated in the phase I study with a single dose of FT825 / ONO-8250 as monotherapy at the first dose level of 100 million cells. Fate plans to present clinical and translational data from the phase I study at a medical conference in the second half of 2024.
A phase I study of FT522 in patients with relapsed/refractory B-cell lymphoma is also ongoing. The first patient has now been treated in the first three-dose cohort at 300 million cells per dose without conditioning chemotherapy. In addition, the first patient has now been treated in the second three-dose cohort at 900 million cells per dose with conditioning chemotherapy (Regimen A). No dose-limiting toxicity or event of any grade of CRS, ICANS, or GvHD has been reported.
Fate plans to submit an investigational new drug application to the FDA in the third quarter of 2024 for the treatment of a basket of B cell-mediated autoimmune diseases with FT522, without any administration of conditioning chemotherapy to patients.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in estimates revision.
The consensus estimate has shifted 12.33% due to these changes.
VGM Scores
At this time, Fate Therapeutics has an average Growth Score of C, however its Momentum Score is doing a bit better with a B. However, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Fate Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Fate Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, SpringWorks Therapeutics (SWTX - Free Report) , a stock from the same industry, has gained 8.9%. The company reported its results for the quarter ended June 2024 more than a month ago.
SpringWorks Therapeutics reported revenues of $59.73 million in the last reported quarter, representing a year-over-year change of